绝经后女性高血压发病机制及防治

摘要/Abstract

摘要： 高血压是临床上最常见的慢性疾病之一，可导致全身各靶器官损害，是心脑血管事件发生的高危因素。在绝经后女性这一特殊群体中，高血压发病率明显上升，具有明显的年龄性别差异。大量研究表明该差异与生殖激素水平变化有关，女性围绝经期及绝经后生殖内分泌的改变与女性高血压的发生有关系，但其发生机制错综复杂，多种机制共同参与，尚需进一步研究证实。目前，绝经后女性高血压疾病不管是发病机制方面，还是预防治疗措施方面，均存在许多争议和不确定性。本研究主要围绕绝经后女性高血压的流行病学、激素分泌特点及临床特点进行分析，深入探讨绝经后高血压的发病机制及防治，以期为该病的临床干预和治疗提供借鉴和参考。

关键词: font-size:medium, ">高血压；绝经；发病机制；防治原则

Abstract: Hypertension is one of the most common chronic diseases in clinical practice， which can damage the target organs of the body and is the high risk factor for cardiovascular and cerebrovascular events. In the population of postmenopausal women， the prevalence of hypertension increased obviously， with significant age and gender differences. A large number of studies have shown that these differences are related to changes in reproductive hormone levels. The changes in female perimenopausal and postmenopausal reproductive endocrine are related to the occurrence of female hypertension.However， its occurrence mechanism is intricate and multiple mechanisms participate together， and further research is needed to confirm. At present， there are many controversies and uncertainties about the pathogenesis or preventive and treatment measures of hypertension in postmenopausal women. In this paper， the epidemidogy， characteristics of hormone secretion and clinical feature of hypertension in postmenopause women were systematically analyzed，and the pathogenesis and prevention of postmenopausal hypertension were in-depth discussed，in order to provide reference for clinical intervention and treatment of the disease.

Key words: font-size:medium, ">Hypertension； Menopause； Pathogenesis； Prevention and treatment principles

中图分类号:

黄文洁, 李晓敏, 卢永超. 绝经后女性高血压发病机制及防治[J]. 中国医药导刊, 2021, 23(1): 6-10.

HUANG Wenjie, LI Xiaomin, LU Yongchao. Pathogenesis and Prevention of Hypertension in Postmenopausal Women[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2021, 23(1): 6-10.

参考文献

[1]中国高血压防治指南2018年修订版[J]. 心脑血管病防治， 2019， 19(1)：1-44.
     [2]韩富磊，杨灵华，张红萍，等.中国不同性别成年居民高血压患病现状及影响因素分析[J]. 中国医院统计， 2019， 26(5)：321-325， 330.
     [3]吴琦欣，史明标，邓燕，等.我国成人高血压流行病学分布特征研究进展[J]. 现代预防医学， 2019， 46(23)：4238-4242.
     [4]李镒冲，王丽敏，姜勇，等.2010年中国成年人高血压患病情况[J]. 中华预防医学杂志， 2012， 46(5)：409-413.
     [5]Zaidi M， Lizneva D， Kim SM， et al. FSH， Bone mass， body fat， and biological aging[J]. Endocrinology， 2018， 159(10)：3503-3514.
     [6]Harlow SD， Gass M， Hall JE， et al. Executive summary of the Stages of Reproductive Aging Workshop + 10： addressing the unfinished agenda of staging reproductive aging[J]. J Clin Endocrinol Metab， 2012， 97(4)：1159-1168.
     [7]Tepper PG， Randolph Jr JF， McConnell DS， et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women′s Health Across the Nation (SWAN)[J]. J Clin Endocrinol Metab， 2012， 97(8)：2872-2880.
     [8]Maas AH， Franke HR. Women′s health in menopause with a focus on hypertension[J]. Neth Heart J， 2009， 17(2)：68-72.
     [9]Alpsoy S， Dogan B， Ozkaramanli GD， et al. Assessment of salusin alpha and salusin beta levels in patients with newly diagnosed dipper and non-dipper hypertension[J]. Clin Exp Hypertens， 2020， 29：1-7.
     [10]Cho L， Davis M， Elgendy I， et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women： JACC state-of-the-art review[J]. J Am Coll Cardiol， 2020， 75(20)：2602-2618.
     [11]Routledge FS， McFetridge-Durdle JA， Dean CR. Stress， menopausal status and nocturnal blood pressure dipping patterns among hypertensive women[J]. Can J Cardiol， 2009， 25(6)：e157-e163.
     [12]Saxena T， Ali AO， Saxena M. Pathophysiology of essential hypertension： an update[J]. Expert Rev Cardiovasc Ther， 2018， 16(12)：879-887.
     [13]Moreau KL， Hildreth KL， Meditz AL， et al. Endothelial function is impaired across the stages of the menopause transition in healthy women[J]. J Clin Endocrinol Metab， 2012， 97(12)：4692-4700.
     [14]Wehbe Z， Nasser SA， El-Yazbi A， et al. Estrogen and bisphenol A in hypertension[J]. Curr Hypertens Rep， 2020， 22(3)：23.
     [15]Sudhir K， Jennings GL， Funder JW， et al. Estrogen enhances basal nitric oxide release in the forearm vasculature in perimenopausal women[J]. Hypertension， 1996， 28(3)：330-334.
     [16]Mijatovic V， van der Mooren MJ. Homocysteine in postmenopausal women and the importance of hormone replacement therapy[J]. Clin Chem Lab Med， 2001， 39(8)：764-767.
     [17]Gaikwad NW. Mass spectrometry evidence for formation of estrogen-homocysteine conjugates： estrogens can regulate homocysteine levels[J]. Free Radic Biol Med， 2013， 65：1447-1454.
     [18]Zhang D， Hong X， Wang J， et al. Estradiol-17β inhibits homocysteine mediated damage by promoting H2S production via upregulating CBS and CSE expression in human umbilical vein endothelial cells[J]. J Cell Biochem， 2019， Nov 14. DOI：10.1002/jcb.29527.
     [19]Riedel K， Deussen AJ， Tolkmitt J， et al. Estrogen determines sex differences in adrenergic vessel tone by regulation of endothelial β-adrenoceptor expression[J]. Am J Physiol Heart Circ Physiol， 2019， 317(2)：h243-h254.
     [20]Wyss JM， Carlson SH. Effects of hormone replacement therapy on the sympathetic nervous system and blood pressure[J]. Curr Hypertens Rep， 2003， 5(3)：241-246.
     [21]Maranon RO， Lima R， Mathbout M， et al. Postmenopausal hypertension： role of the sympathetic nervous system in an animal model[J]. Am J Physiol Regul Integr Comp Physiol， 2014， 306(4)：R248-256.
     [22]Olszanecka A， Dragan A， Kawecka-Jaszcz K， et al. Influence of metabolic syndrome and its components on subclinical organ damage in hypertensive perimenopausal women[J]. Adv Med Sci， 2014， 59(2)：232-239.
     [23]Oh GC， Kang KS， Park CS， et al. Metabolic syndrome， not menopause， is a risk factor for hypertension in peri-menopausal women[J]. Clin Hypertens， 2018， 24：14.
     [24]Olszanecka A， Dragan A， Kawecka-Jaszcz K， et al. Relationships of insulin-like growth factor-1， its binding proteins， and cardiometabolic risk in hypertensive perimenopausal women[J]. Metabolism， 2017， 69：96-106.
     [25]Wen HJ， Liu GF， Xiao LZ， et al. Involvement of endothelial nitric oxide synthase pathway in IGF-1 protects endothelial progenitor cells against injury from oxidized LDLs[J]. Mol Med Rep， 2019， 19(1)：660-666.
     [26]Artunc F， Schleicher E， Weigert C， et al. The impact of insulin resistance on the kidney and vasculature[J]. Nat Rev Nephrol， 2016， 12(12)：721-737.
     [27]Salvetti A， Brogi G， Di Legge V， et al. The inter-relationship between insulin resistance and hypertension[J]. Drugs， 1993， 46（Suppl 2）：149-159.
     [28]Davis SN， Colburn C， Dobbins R， et al. Evidence that the brain of the conscious dog is insulin sensitive[J]. J Clin Invest， 1995， 95(2)：593-602.
     [29]Vallée A， Lévy BL， Blacher J. Interplay between the renin-angiotensin system， the canonical WNT/β-catenin pathway and PPARγ in hypertension[J]. Curr Hypertens Rep， 2018， 20(7)：62.
     [30]Satou R， Penrose H， Navar LG. Inflammation as a regulator of the renin-angiotensin system and blood pressure[J]. Curr Hypertens Rep， 2018， 20(12)：100.
     [31]陈源源.围绝经期高血压[J]. 中华老年心脑血管病杂志， 2017， 19(6)：670-672.
     [32]邱璐，庄欣.围绝经期高血压发病机制及激素替代疗法研究进展[J]. 世界最新医学信息文摘， 2019， 19(28)：38-40.
     [33]Masi S， Uliana M， Virdis A. Angiotensin Ⅱ and vascular damage in hypertension： Role of oxidative stress and sympathetic activation[J]. Vascul Pharmacol， 2019， 115：13-17.
     [34]Sylvester MA， Brooks HL. Sex-specific mechanisms in inflammation and hypertension[J]. Curr Hypertens Rep， 2019， 21(7)：53.
     [35]Zeng X， Dai J， Remick DG， et al. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes[J]. Circ Res， 2003， 93(4)：311-320.
     [36]Natali A， Ferrannini E. Hypertension， insulin resistance， and the metabolic syndrome[J]. Endocrinol Metab Clin North Am， 2004， 33(2)：417-429.
     [37]Grillo A， Salvi L， Coruzzi P， et al. Sodium intake and hypertension[J]. Nutrients，2019，11(9)：1970.
     [38]Gohar EY， Daugherty EM， Aceves JO， et al. Evidence for G-Protein-Coupled estrogen receptor as a pronatriuretic factor[J]. J Am Heart Assoc， 2020， 9(10)：e015110.
     [39]Taneja C， Gera S， Kim SM， et al. FSH-metabolic circuitry and menopause[J]. J Mol Endocrinol， 2019， 63(3)：r73-r80.
     [40]Zhu D， Li X， Macrae VE， et al. Extragonadal effects of follicle-stimulating hormone on osteoporosis and cardiovascular disease in women during menopausal transition[J]. Trends Endocrinol Metab， 2018， 29(8)：571-580.
     [41]El Khoudary SR， Santoro N， Chen HY， et al. Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause[J]. Eur J Prev Cardiol， 2016， 23(7)：694-703.
     [42]Mahmood S， Shah KU， Khan TM， et al. Non-pharmacological management of hypertension： in the light of current research[J]. Ir J Med Sci， 2019， 188(2)：437-452.
     [43]Turnbull F， Woodward M， Neal B， et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials[J]. Eur Heart J， 2008， 29(21)：2669-2680.
     [44]Collins P， Rosano G， Casey C， et al. Management of cardiovascular risk in the perimenopausal women： a consensus statement of European cardiologists and gynecologists[J]. Climacteric， 2007， 10(6)：508-526.
     [45]Mueck AO， Seeger H. Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women[J]. Maturitas， 2004， 49(3)：189-203.
     [46]Affinito P， Palomba S， Bonifacio M， et al. Effects of hormonal replacement therapy in postmenopausal hypertensive patients[J]. Maturitas， 2001， 40(1)：75-83.
     [47]Scuteri A， Bos AJ， Brant LJ， et al. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women[J]. Ann Intern Med， 2001， 135(4)：229-238.
     [48]Marques-Lopes J， Tesfaye E， Israilov S， et al. Redistribution of NMDA receptors in estrogen-receptor-beta-containing paraventricular hypothalamic neurons following slow-pressor angiotensin Ⅱ hypertension in female mice with accelerated ovarian failure[J]. Neuroendocrinology， 2017， 104(3)：239-256.
     [49]Lobo RA. Hormone-replacement therapy： current thinking[J]. Nat Rev Endocrinol， 2017， 13(4)：220-231.
     [50]Collins P， Rosano G， Casey C， et al. Management of cardiovascular risk in the peri-menopausal woman： a consensus statement of European cardiologists and gynaecologists[J]. Eur Heart J， 2007， 28(16)：2028-2040.

快速检索引用检索图表检索高级检索